OBJECTIVES: During the last decade many new biological immune modulators have entered the market as new therapeutic principles. Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine known to a have a key role in the pathogenic mechanisms of various immune-mediated or inflammatory diseases. However, TNF-α also plays a key role in endothelial dysfunction and, thus, in the development and progression of atherosclerosis. What, then, is the potential therapeutic role of TNF-α inhibitors? METHODS: We analysed the current literature concerning the administration of TNF-α inhibitors and their potential benefits upon endothelial function. RESULTS: TNF-α inhibitors decrease the serum levels of inflammatory markers such as TNF-α itself, CRP, IL-6, and increased the tissue expression of endothelial NO synthase and the vasodilatory response to bradykinin. DISCUSSION: TNF-α inhibitors may change the progression of endothelial dysfunction and, thus, slow down the atherosclerotic process.
OBJECTIVES: During the last decade many new biological immune modulators have entered the market as new therapeutic principles. Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine known to a have a key role in the pathogenic mechanisms of various immune-mediated or inflammatory diseases. However, TNF-α also plays a key role in endothelial dysfunction and, thus, in the development and progression of atherosclerosis. What, then, is the potential therapeutic role of TNF-α inhibitors? METHODS: We analysed the current literature concerning the administration of TNF-α inhibitors and their potential benefits upon endothelial function. RESULTS: TNF-α inhibitors decrease the serum levels of inflammatory markers such as TNF-α itself, CRP, IL-6, and increased the tissue expression of endothelial NO synthase and the vasodilatory response to bradykinin. DISCUSSION: TNF-α inhibitors may change the progression of endothelial dysfunction and, thus, slow down the atherosclerotic process.
Authors: J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal Journal: Arthritis Rheum Date: 2001-10
Authors: E Profumo; B Buttari; C Alessandri; F Conti; R Capoano; G Valesini; B Salvati; R Riganò Journal: Int J Immunopathol Pharmacol Date: 2010 Jan-Mar Impact factor: 3.219
Authors: Marc C Hochberg; Mark G Lebwohl; Scott E Plevy; Kathryn F Hobbs; David E Yocum Journal: Semin Arthritis Rheum Date: 2005-06 Impact factor: 5.532
Authors: Giorgio Ciprandi; Giuseppe Murdaca; Barbara Maria Colombo; Mara De Amici; Gialuigi L Marseglia Journal: Hum Immunol Date: 2008-06-23 Impact factor: 2.850
Authors: Mariam El Assar; Javier Angulo; Esther García-Rojo; Alejandro Sevilleja-Ortiz; Borja García-Gómez; Argentina Fernández; Alberto Sánchez-Ferrer; José M La Fuente; Javier Romero-Otero; Leocadio Rodríguez-Mañas Journal: Geroscience Date: 2021-12-28 Impact factor: 7.713
Authors: Emmanuelle Rollet-Labelle; Myriam Vaillancourt; Louis Marois; Marianna M Newkirk; Patrice E Poubelle; Paul H Naccache Journal: J Inflamm (Lond) Date: 2013-07-31 Impact factor: 4.981
Authors: Luca Goitre; Peter V DiStefano; Andrea Moglia; Nicholas Nobiletti; Eva Baldini; Lorenza Trabalzini; Julie Keubel; Eliana Trapani; Vladimir V Shuvaev; Vladimir R Muzykantov; Ingrid H Sarelius; Saverio Francesco Retta; Angela J Glading Journal: Sci Rep Date: 2017-08-15 Impact factor: 4.379
Authors: Lana Claudinez dos Santos; Aline Villela Costa; Lorrayne Gonçalves Lopes; Alda Jusceline Leonel; Edenil Costa Aguilar; Maria de Lourdes Meirelles Noviello; Maria de Lourdes de Abreu Ferrari; Jacqueline I Alvarez-Leite Journal: Med Sci Monit Date: 2015-08-07